Colchicine may become a new cornerstone therapy for coronary artery disease: a meta-analysis of randomized controlled trials.
Yi ChenHongzhou ZhangYuxin ChenMeng LiWei LuoYue LiuYang FuHuasong XiaCong XuYu JiangYan-Qing WuPublished in: Clinical rheumatology (2022)
Colchicine treatment significantly decreased the risk of primary cardiovascular composite outcomes, MI, ischemic stroke, and ischemia-driven coronary revascularization in CAD patients but increased adverse GI events. There was no significant difference in all-cause mortality, cardiovascular mortality, and non-cardiovascular death between the colchicine and control groups. Colchicine performs better in acute CAD patients with ischemic stroke than chronic CAD patients. Colchicine might be a new treatment for patients with CAD.
Keyphrases
- coronary artery disease
- end stage renal disease
- newly diagnosed
- percutaneous coronary intervention
- cardiovascular events
- coronary artery bypass grafting
- chronic kidney disease
- prognostic factors
- atrial fibrillation
- emergency department
- type diabetes
- cardiovascular disease
- coronary artery
- liver failure
- skeletal muscle
- aortic valve
- combination therapy